AVMBioMed is a contract research organization (CRO) founded in 2013 and based in the United States. The company specializes in the novel discovery of post-translational modifications (PTM) and has developed Snapshot Proteomics™ technology, which utilizes protein microarrays to capture PTMs from complex mixtures like cell extracts and patient samples. This technology also identifies specific protein-protein interactions and reveals novel enzyme-substrate pairings. AVMBioMed's services offer powerful and novel information for basic science, target validation, preclinical compound characterization, and biomarker discovery. The company's focus on cutting-edge technology and its potential to impact various industries make it an intriguing prospect for investors looking to support innovative ventures in the life sciences and technology sectors. For more information, you can visit their website at www.avmbiomed.com.
There is no investment information
No recent news or press coverage available for AVMBioMed.
We care about your data, and we'd love to use cookies make your experience better.
